This legal document, a “Defendant’s Reply in Support of Second Motion to Continue Sentencing,” outlines Dr. Neil K. Anand’s arguments for delaying his sentencing. The defense primarily asserts two critical issues: first, a complete breakdown of the attorney-client relationship that infringes upon Dr. Anand’s Sixth Amendment rights, necessitating new counsel and preparation time. Second, the filing highlights newly discovered systemic evidence undermining the reliability of drug weight and financial calculations used by the prosecution. This includes pervasive errors in Pennsylvania’s Prescription Drug Monitoring Program (PDMP)
from youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, IN THE SPIRIT OF WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS


Introduction and Overview
This briefing document summarizes key themes, ideas, and facts presented in Neil K. Anand’s “DEFENDANT’S REPLY IN SUPPORT OF SECOND MOTION TO CONTINUE SENTENCING,” along with supporting exhibits (NA-42, NA-43, NA-44, NA-45, NA-46, NA-47).

The motion seeks a continuance of Dr. Anand’s sentencing hearing, citing fundamental constitutional concerns due to an irreparable breakdown in the attorney-client relationship, newly discovered systemic evidence undermining drug weight calculations, and widespread factual inaccuracies in the government’s financial and patient data.

The core arguments revolve around:
- Sixth Amendment Violations: The complete deterioration of Dr. Anand’s relationship with his current counsel prevents effective representation.
- Unreliable Drug Weight Calculations: The Pennsylvania Prescription Drug Monitoring Program (PDMP) data from the ABC-MAP system, which forms the basis of the drug weight calculations, is fundamentally unreliable due to acknowledged systemic errors and is unsuitable for precise sentencing calculations under U.S.S.G. §2D1.1.
- Government’s Flawed Methodology: The prosecution’s reliance on a “hand-selected sample of just 14 patients” and algorithmic tools (DEA’s “Nemesis” Deloitte system, “Isolation Forest” algorithms) is biased, scientifically invalid, and undermines due process.
- Widespread Factual Errors in Government Exhibits: Significant accounting discrepancies and numerous inaccuracies in the government’s financial and patient files invalidate key allegations.
- Impermissible Expansion of Federal Power: The prosecution criminalizes legitimate medical judgment based on statistical anomalies, violating fundamental principles of criminal law and medical practice and encroaching on state authority.

II. Key Themes and Most Important Ideas/Facts
1. Irreparable Breakdown of Attorney-Client Relationship (Sixth Amendment Concern)
- Core Issue: Dr. Anand asserts an “irreparable breakdown of the attorney-client relationship with irreconcilable differences,” which is not merely a procedural issue but a “fundamental constitutional issue.”
- Consequences: “When an attorney-client relationship has deteriorated to the point where effective representation is impossible, the Sixth Amendment requires that new counsel be appointed and granted a reasonable time to prepare.”
- Specific Differences: The irreconcilable differences include:
- “Fundamental disagreements regarding sentencing strategy”
- “Communication breakdowns preventing proper preparation”
- “Complete loss of confidence in counsel’s ability to effectively advocate”
- Legal Precedent: Proceeding under these conditions would violate Dr. Anand’s constitutional rights and deny the Court “the benefit of fully prepared and unified advocacy at a critical stage.” (United States v. Welty, 674 F.2d 185, 188 (3d Cir. 1982); Wheat v. United States, 486 U.S. 153, 159 (1988)).
- Exemplified in Exhibits: Exhibit NA-42, while largely a collection of email exchanges related to financial analysis and legal research, implicitly supports the breakdown by showing Dr. Anand actively conducting detailed financial analysis and legal research (e.g., on USA v. Dr. Patrick Titus and Michael Petron’s cross-examination) and directly communicating findings to his counsel, indicating a high level of personal involvement and potential disagreement on strategy or confidence in counsel’s handling of these areas. For instance, Dr. Anand sends an email titled “Finished Financial Analysis for Ganoway” to his counsel, outlining specific financial analysis and asking for questions, which could be interpreted as him taking on tasks typically managed by legal teams due to a lack of confidence or communication. Another email states, “Reviewed some of the government exhibits with Neil, that Petron will probably be using. And they don’t make sense. Happy to get on zoom and go over. Attaching here with commentary if you can decipher what I am saying,” from Cathleen London to Neil Anand and his counsel, further suggesting issues with the defense’s understanding or handling of government evidence.

2. Unreliability of PDMP Data for Drug Weight Calculations
- Foundation of the Problem: The “entire foundation of the drug weight calculation: Pennsylvania’s Prescription Drug Monitoring Program (PDMP) data from the ABC-MAP system” is unreliable.
- Systemic Errors (Exhibit NA-44): Recent review of PDMP’s official documentation reveals structural incapacity to produce reliable data for U.S.S.G. §2D1.1 calculations due to “multiple acknowledged error pathways.”
- “Fatal Errors”: If >10% of records in a file have fatal errors, “the entire file is rejected—meaning ‘no records in it are loaded, including those without any errors.'” This leads to “wholesale data exclusion” and “unpredictable gaps” causing “cascading undercounts.”
- “Serious Errors”: The system loads records with “missing or inappropriate data,” including “incorrect drug quantities, dosages, and identification codes” (e.g., “NDC Not Found,” “Dispenser DEA Invalid,” missing quantity fields). This “artificially inflat[es] or deflat[es] totals unpredictably.”
- Patient Matching Errors: PDMP “explicitly warns: ‘Occasionally, 2 people will show up on a single PDMP report… This most often occurs when both parties have the same birth date or same street name or when there are multiple pieces of overlapping information and our computer is unable to isolate one unique patient.'” This results in “prescriptions being counted multiple times for a single individual, directly and unfairly inflating drug weight calculations.”
- Official Disclaimers: Pennsylvania’s own disclaimers confirm data “unsuitability for precise calculations,” citing “Attribution Errors,” “Incomplete Data,” and “Systematic Gaps.”
- Legal Precedent: Using such data violates “fundamental due process protections” (In re Winship, 397 U.S. 358, 364 (1970)) and Federal Sentencing Guidelines which “demand precision” (United States v. Kikumura, 918 F.2d 1084, 1098 (3d Cir. 1990): “the government must prove drug quantities by a preponderance of the evidence, and the evidence must be sufficiently reliable to support the finding.”).
- Specific Evidence: Dr. Anand “has already identified numerous errors within the Government data set and with patients that Defendant Anand has been convicted for” (Exhibit NA-43, NA-44). Exhibit NA-43 is a placeholder for specific examples of PDMP errors. Email correspondence in NA-42 confirms Dr. Anand’s team identified PDMP errors (e.g., “Did Petron/Stout clean up the PDMP data before analysis? Did they take out errors (wrong prescriber, double entries etc?) If he says there are none, use the examples Neil has provided to impeach with.”).

3. Government’s Flawed Algorithmic Prosecution Framework
- Biased Sample Selection: The government’s case “was built almost entirely on a hand-selected sample of just 14 patients, representing a mere 2% of his total patient population.” Defense analysis showed this selection was “deliberately biased toward identifying outliers,” with a probability of random occurrence “greater than 1 in 2 million.”
- Contradictory Evidence: Dr. Anand’s “complete prescribing patterns against national Medicare data showed practices well within mainstream norms: Overall Prescribing Volume: 29th percentile; Opioid Claims Volume: 42nd percentile; Opioid Prescribing Rate: 77th percentile.” This means “77% of pain physicians had more aggressive opioid prescribing than Dr. Anand.”
- DEA’s “Nemesis” Deloitte System & Isolation Forest Algorithm: The government’s case relied heavily on this “anomaly detection system” which “identif[ies] statistical outliers” and “flags physicians whose prescribing patterns deviate from algorithmic norms.”
- Prosecutorial Bias: Dr. King’s patent application (US 20200143925A1) explicitly states he “aids in the criminal prosecution of pill mills,” revealing the methodology was “specifically designed to support criminal prosecutions… not to provide objective medical evaluation.” The approach “assumes Criminal Intent” from “statistical deviation.”
- Scientific Invalidity (Daubert Standards): The Isolation Forest algorithm is an “unsupervised machine learning algorithm that identifies statistical outliers without any training on what constitutes ‘appropriate’ versus ‘inappropriate’ medical care.”
- “Cannot Be Tested for Medical Appropriateness”
- “No Relevant Error Rates for Criminal Applications” (e.g., “94% false positive rate” in credit card fraud detection)
- “Lacks General Acceptance in Medical Community”
- Algorithmic Pitfalls: Technical analysis reveals “swamping and masking effects” and “high-dimensional data problems” making it unreliable for complex medical data. “Parameter Sensitivity Requires Domain Expertise,” which the DEA lacks.
- DEA Risk Factors Criminalize Legitimate Practice: The “50+ risk factors” systematically bias against appropriate pain management by:
- MME Thresholds: Penalizing MME >= 100, despite medical literature supporting high doses for chronic pain.
- Geographic Factors: Penalizing travel distance to pharmacy/prescriber, discriminating against patients in underserved areas.
- Prescription Patterns: Flagging “Trinity combinations” (opioid + benzodiazepine + muscle relaxant) and multiple pharmacy use, which may be medically appropriate.
- Patient Criminal History: The DEA’s use of “patient criminal history as an input for algorithmic risk scoring” violates due process, equal protection, and medical ethics, effectively “criminalizes the treatment of vulnerable populations” and reintroduces punishment for individuals who completed sentences.
- Additional Distortions: The government’s methodology also involved “Temporal Manipulation” (using “written date” not “fill date” to create “spikes”), “Expert Financial Bias” (Dr. King earning “millions of dollars”), and “Selective Evidence.”
- Legal Precedent: This algorithmic approach “violates Titus,” which “vacated a sentence based on unreliable drug quantity calculations” where extrapolation from a sample was not “statistically valid” or “consistent with accepted standards of reliability.” (United States v. Titus, No. 22-1516 (3d Cir. 2023)).

4. Widespread Factual Inaccuracies in Government Exhibits
- Accounting Discrepancies (Exhibit NA-45): Government Exhibits 210 and 211 show a “fundamental accounting impossibility.” Total PBM payments were “$2,960,583,” but total non-pharmacy account receipts were “$3,870,273″—a discrepancy of “$909,690 more received than paid.”
- Specifically, TD Bank Account 7033 alone received “$3,281,773,” approximately “$321,190 higher than the total pharmacy payments.” This “violates basic accounting principles.” Exhibit NA-45 visually represents these transfers and the discrepancy.
- File Inaccuracies (Files 309A, 304, 301, 303, 722): Defense identified “widespread inaccuracies” misrepresenting “over $700,000 in alleged payments.” Email correspondence in NA-42, specifically an email from Neil Anand titled “Request for Court Hearing – Fraudulent Claims in Govt Files 309A, 304, 301, 303, and 722” explicitly details these errors and requests a hearing, independent audit, and exclusion of these files.
- File 309A – Systematic False Claims: “Quadruple Counting of Claims,” “Claims from Unassociated Physicians,” “Factual Impossibilities” (claims predating IAMS Pharmacy’s creation), and “False Payment Representations.”
- Specific Patient Payment Misrepresentations: Detailed examples with patients like Tamara Gage, Rochelle Morrow, Stanley Chmura, Joseph Tinneny, Thomas Boyd, and Naikema Good, where “Independence Blue Cross fraudulently claims they paid the same claims” or reported incorrect amounts compared to actual EOBs (Exhibit NA-46 is a placeholder for such documentation).
- Misattributed Provider Claims: Claims paid to Dr. Kaplan were “fraudulently attributed to Dr. Anand.”
- Non-Member Fraud: Claims for Tracy Perfidio by IBC were “impossible” as she “was not an IBC member” then.
- Additional Deficiencies: File 304 “falsely attributes payments for services rendered by other providers to Dr. Anand,” Files 301 & 303 “include patients never treated by Dr. Anand,” and File 722 “contains prescriptions not written by Dr. Anand.” Exhibit NA-47 is a placeholder for specific examples of these file discrepancies.

FORMER U.S. SENATOR ORRIN HATCH (R) UTAH: STATED GOAL OF D.E.A. AND BILL SIGNED INTO LAW TO CHECK ITS ABUSES
CLICK BELOW
FORMER SENATOR ORRIN HATCH OF UTAH
5. Impermissible Expansion of Federal Power
- Criminalization of Medical Judgment: The prosecution “fundamentally misrepresents the nature of legitimate medical practice by relying on a statistically manipulated and non-representative sample that transforms ordinary physician conduct into alleged criminal behavior.”
- Violations of Legal Principles:Statutory Prohibition: 42 U.S.C. § 1395’s “explicit bar against federal interference in medical practice.”
- Constitutional Limits (Commerce Clause): United States v. Lopez, 514 U.S. 549 (1995) and United States v. Morrison, 529 U.S. 598 (2000) establish that federal regulation is only permissible for “economic activity that substantially affects interstate commerce” or “non-economic activity where the jurisdictional nexus is demonstrated on a case-by-case basis.” Medical prescribing is “quintessentially non-economic activity.”
- Criminal Law Standards: United States v. Moore, 423 U.S. 122 (1975) demands “rigorous evidentiary requirements for prescription drug prosecutions,” requiring proof that prescriptions were “not for a legitimate medical purpose” and “outside the usual course of professional practice.”
- Substantive Due Process Violation: The prosecution “criminalizes legitimate medical judgment,” imposing a “chilling effect on the exercise of these rights” for physicians and patients. It “substitutes law enforcement metrics for medical expertise, stripping medicine of its professional autonomy.”
- Proper Remedy: “The proper remedy for prescribing practices that may warrant scrutiny is state medical board oversight, not federal criminal prosecution based on statistical analysis.”
III. Conclusion and Requested Continuance
A continuance is essential to:
- Resolve the “constitutional crisis from attorney-client breakdown.”
- Conduct “forensic analysis of specific PDMP data used in the PSR to identify and quantify systematic errors.”
- Prepare a motion to “exclude unreliable PDMP data or apply statistical reductions for known error rates.”
- Fully brief the Court on “actual healthcare fraud losses” and “compelling Titus implications.”
- Investigate “file discrepancies in government exhibits forming the basis of allegations.”
Proceeding without addressing these issues would “compromise this Court’s proceedings and create significant appellate vulnerability,” as the “integrity of federal sentencing demands drug weight calculations based on reliable, accurate evidence.”
TO CASH APP:$docnorm
ZELLE 3135103378

ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!


FOR NOW, YOU ARE WITHIN
THE NORMS